Skip to main content

Drug Interactions between carbamazepine and doxepin topical

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

carBAMazepine doxepin topical

Applies to: carbamazepine and doxepin topical

MONITOR: Carbamazepine may decrease serum concentrations of tricyclic antidepressants. The mechanism may be related to carbamazepine induction of CYP450 enzymes responsible for tricyclic antidepressant metabolism. Serum concentrations of carbamazepine may be increased by an unknown mechanism. Carbamazepine toxicity has been reported with desipramine. Additionally, tricyclic antidepressants may counteract the anticonvulsant effects of carbamazepine by lowering the seizure threshold.

MANAGEMENT: Clinical monitoring of serum concentrations, patient response, seizure control, and tolerance is recommended whenever either agent is added to or discontinued from an existing regimen, or when the dosage is changed.

References (5)
  1. Brown CS, Wells BG, Cold JA, Froemming JH, Self TH, Jabbour JT (1990) "Possible influence of carbamazepine on plasma imipramine concentrations in children with attention deficit hyperactivity disorder." J Clin Psychopharmacol, 10, p. 359-62
  2. Leinonen E, Lillsunde P, Laukkanen V, Ylitalo P (1991) "Effects of carbamazepine on serum antidepressant concentrations in psychiatric patients." J Clin Psychopharmacol, 11, p. 313-8
  3. Brosen K, Kragh-Sorensen P (1993) "Concomitant intake of nortriptyline and carbamazepine." Ther Drug Monit, 15, p. 258-60
  4. Jerling M, Bertilsson L, Sjoqvist F (1994) "The use of therapeutic drug monitoring data to document kinetic drug interactions: an example with amitriptyline and nortriptyline." Ther Drug Monit, 16, p. 1-2
  5. Spina E, Avenoso A, Campo GM, Caputi AP, Perucca E (1995) "The effect of carbamazepine on the 2-hydroxylation of desipramine." Psychopharmacology (Berl), 117, p. 413-6

Drug and food interactions

Moderate

carBAMazepine food

Applies to: carbamazepine

GENERALLY AVOID: Alcohol may potentiate some of the pharmacologic effects of carbamazepine. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.

In a small, randomized, crossover study, the administration of carbamazepine with grapefruit juice (compared to water) increased plasma drug concentrations by approximately 40%. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.

MANAGEMENT: Patients receiving carbamazepine should be advised to avoid or limit consumption of alcohol. Given the drug's narrow therapeutic index, patients receiving carbamazepine therapy should preferably avoid the regular consumption of grapefruits and grapefruit juice to prevent any undue fluctuations in plasma drug levels. Patients should be advised to report signs of carbamazepine toxicity (nausea, visual disturbances, dizziness, or ataxia) to their physicians.

References (3)
  1. (2002) "Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals
  2. Garg SK, Kumar N, Bhargava VK, Prabhakar SK (1998) "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther, 64, p. 286-8
  3. Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR (2000) "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther, 68, p. 468-77

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer